ACM
ANEB

ADAR1 Capital Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

ADAR1 Capital Management’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,217
Closed -$2.94K – 264
2023
Q4 		$2.94K Buy
+1,217
New +$2.86K ﹤0.01% 154

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

ADAR1 Capital Management's ANEB Position: Q1 2024 in Review

ADAR1 Capital Management sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2024, closing a stake of 1,217 shares — an estimated $2.94K sold.

ADAR1 Capital Management first reported a position in ANEB in Q4 2023 and held it in 1 quarter. The position peaked at $2.94K in Q4 2023. 15 funds tracked by Wall St. Rank hold ANEB as of Q1 2024.

  • ADAR1 Capital Management reported no remaining Anebulo Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 1,217 Anebulo Pharmaceuticals shares in Q1 2024, an estimated $2.94K.
  • ADAR1 Capital Management first reported a position in Anebulo Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • ADAR1 Capital Management's Anebulo Pharmaceuticals position peaked at $2.94K in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2024.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.